Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
$11.47
$2.66
$32.75
$48.64M2.5795,409 shs43,300 shs
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
$729.62
-0.5%
$752.67
$279.02
$830.21
$56.80B1.29545,551 shs1.12 million shs
Immunic, Inc. stock logo
IMUX
Immunic
$0.83
-0.9%
$0.84
$0.56
$2.11
$79.54M1.49983,404 shs439,488 shs
NextCure, Inc. stock logo
NXTC
NextCure
$0.40
-15.6%
$0.47
$0.22
$1.82
$11.08M1.06130,159 shs395,101 shs
Trevena, Inc. stock logo
TRVN
Trevena
$0.94
-5.5%
$1.09
$0.73
$7.85
$897K0.612,066 shs462 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
0.00%0.00%0.00%0.00%0.00%
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
0.00%-8.28%-5.88%+28.46%+148.77%
Immunic, Inc. stock logo
IMUX
Immunic
0.00%+13.87%-1.64%-7.79%-35.15%
NextCure, Inc. stock logo
NXTC
NextCure
0.00%-9.61%-39.26%+35.74%-75.00%
Trevena, Inc. stock logo
TRVN
Trevena
0.00%-0.51%-7.41%-17.24%-83.34%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
2.0872 of 5 stars
2.43.00.00.04.12.50.0
Immunic, Inc. stock logo
IMUX
Immunic
2.3936 of 5 stars
3.61.00.00.02.22.50.6
NextCure, Inc. stock logo
NXTC
NextCure
4.5236 of 5 stars
3.33.00.04.33.51.71.3
Trevena, Inc. stock logo
TRVN
Trevena
1.8679 of 5 stars
3.03.00.00.02.80.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
0.00
N/AN/AN/A
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
2.77
Moderate Buy$699.55-4.12% Downside
Immunic, Inc. stock logo
IMUX
Immunic
3.25
Buy$11.601,297.42% Upside
NextCure, Inc. stock logo
NXTC
NextCure
2.67
Moderate Buy$3.50786.08% Upside
Trevena, Inc. stock logo
TRVN
Trevena
2.00
Hold$5.00434.64% Upside

Current Analyst Ratings Breakdown

Latest NXTC, IMUX, AXON, TRVN, and AGLE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
NextCure, Inc. stock logo
NXTC
NextCure
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
7/7/2025
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
7/1/2025
NextCure, Inc. stock logo
NXTC
NextCure
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00
6/25/2025
Immunic, Inc. stock logo
IMUX
Immunic
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
6/5/2025
Immunic, Inc. stock logo
IMUX
Immunic
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
6/4/2025
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$750.00 ➝ $895.00
5/29/2025
Immunic, Inc. stock logo
IMUX
Immunic
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$17.00 ➝ $10.00
5/23/2025
Immunic, Inc. stock logo
IMUX
Immunic
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $5.00
5/16/2025
Immunic, Inc. stock logo
IMUX
Immunic
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
5/14/2025
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$730.00 ➝ $830.00
5/9/2025
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$726.00 ➝ $735.00
(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
$2.33M0.00N/AN/A($60.61) per share0.00
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
$2.23B25.51$2.79 per share261.89$30.52 per share23.91
Immunic, Inc. stock logo
IMUX
Immunic
N/AN/AN/AN/A$0.20 per shareN/A
NextCure, Inc. stock logo
NXTC
NextCure
N/AN/AN/AN/A$2.34 per shareN/A
Trevena, Inc. stock logo
TRVN
Trevena
$443K2.02N/AN/A($11.07) per share-0.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
-$83.82M-$75.59N/AN/AN/A-22,195.36%-132.05%-146.87%N/A
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
$377.03M$4.14176.24219.1183.9914.86%5.81%2.83%8/5/2025 (Estimated)
Immunic, Inc. stock logo
IMUX
Immunic
-$100.51M-$1.23N/AN/AN/AN/A-326.95%-181.34%8/6/2025 (Estimated)
NextCure, Inc. stock logo
NXTC
NextCure
-$55.65M-$1.76N/AN/AN/AN/A-70.16%-58.10%7/30/2025 (Estimated)
Trevena, Inc. stock logo
TRVN
Trevena
-$40.29M-$47.04N/AN/AN/AN/AN/A-119.55%8/6/2025 (Estimated)

Latest NXTC, IMUX, AXON, TRVN, and AGLE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
NextCure, Inc. stock logo
NXTC
NextCure
-$0.39N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
$1.54N/AN/AN/A$641.77 millionN/A
5/15/2025Q1 2025
Immunic, Inc. stock logo
IMUX
Immunic
-$0.25-$0.25N/A-$0.25N/AN/A
5/7/2025Q1 2025
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
$1.34$1.41+$0.07$1.08$585.67 million$603.63 million
5/1/2025Q1 2025
NextCure, Inc. stock logo
NXTC
NextCure
-$0.40-$0.39+$0.01-$0.39N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
N/AN/AN/AN/AN/A
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
N/AN/AN/AN/AN/A
Immunic, Inc. stock logo
IMUX
Immunic
N/AN/AN/AN/AN/A
NextCure, Inc. stock logo
NXTC
NextCure
N/AN/AN/AN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
N/A
4.59
4.59
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
0.68
2.83
2.62
Immunic, Inc. stock logo
IMUX
Immunic
N/A
0.74
0.74
NextCure, Inc. stock logo
NXTC
NextCure
N/A
10.26
10.26
Trevena, Inc. stock logo
TRVN
Trevena
N/A
2.42
2.42

Institutional Ownership

CompanyInstitutional Ownership
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
N/A
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
79.08%
Immunic, Inc. stock logo
IMUX
Immunic
51.82%
NextCure, Inc. stock logo
NXTC
NextCure
42.65%
Trevena, Inc. stock logo
TRVN
Trevena
13.56%

Insider Ownership

CompanyInsider Ownership
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
6.60%
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
4.40%
Immunic, Inc. stock logo
IMUX
Immunic
4.60%
NextCure, Inc. stock logo
NXTC
NextCure
17.90%
Trevena, Inc. stock logo
TRVN
Trevena
2.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aeglea BioTherapeutics, Inc. stock logo
AGLE
Aeglea BioTherapeutics
694.05 million3.78 millionOptionable
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
4,97077.85 million74.43 millionOptionable
Immunic, Inc. stock logo
IMUX
Immunic
7095.82 million91.41 millionOptionable
NextCure, Inc. stock logo
NXTC
NextCure
9028.05 million23.03 millionOptionable
Trevena, Inc. stock logo
TRVN
Trevena
40959,000841,000Optionable

Recent News About These Companies

Trevena, Inc. (TRVN) - Yahoo Finance
JMP Securities downgrades Trevena (TRVN) to a Hold
Lyme Regis town councillor John Trevena stand down
Trevena appoints new financial chief
Trevena Appoints Katrine Sutton as New CFO
HC Wainwright & Co. Downgrades Trevena (TRVN)
Why Trevena (TRVN) Stock Is Down 43% Today
Trevena, Inc. Faces Delisting from Nasdaq
Trevena Announces Receipt of Nasdaq Delisting Notification
Learn to Evaluate (TRVN) using the Charts

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aeglea BioTherapeutics stock logo

Aeglea BioTherapeutics NASDAQ:AGLE

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Axon Enterprise stock logo

Axon Enterprise NASDAQ:AXON

$729.62 -3.37 (-0.46%)
As of 07/11/2025 04:00 PM Eastern

Axon Enterprise, Inc. develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence. Its products include axon officer safety plan; taser 10, taser7, taser X26P, taser X2, taser 7 CQ, and civilian series; cameras, such as axon body, axon flex, axon fleet, axon air, axon signal sidearm, axon signal vehicle, axon interview, and axon interview portable kit; software, including axon records, evidence, standards, commander, performance, auto-transcribe, justice, investigate, respond, and justice, my90, and redaction assistant; mobile applications, and training services, as well as hardware extended warranties; and Axon docks, cartridges, and batteries. The company sells its products through its direct sales, distribution partners, online store, and third-party resellers. Axon Enterprise, Inc. has a strategic partnership with Fusus, Inc. to expand bility to aggregate live video, data, and sensor feeds. It serves law enforcement, federal, correction, fire, EMS, campus, justice healthcare, retail, private security, and personal safety industries. The company was formerly known as TASER International, Inc. and changed its name to Axon Enterprise, Inc. in April 2017. Axon Enterprise, Inc. was incorporated in 1993 and is headquartered in Scottsdale, Arizona.

Immunic stock logo

Immunic NASDAQ:IMUX

$0.83 -0.01 (-0.92%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$0.84 +0.01 (+1.31%)
As of 07/11/2025 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

NextCure stock logo

NextCure NASDAQ:NXTC

$0.40 -0.07 (-15.63%)
Closing price 07/11/2025 03:59 PM Eastern
Extended Trading
$0.43 +0.04 (+9.62%)
As of 07/11/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Trevena stock logo

Trevena NASDAQ:TRVN

$0.94 -0.05 (-5.50%)
As of 07/11/2025 12:43 PM Eastern

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.